BRIEF-BridgeBio Pharma To Offer $500 Million Convertible Senior Notes Due 2031

Reuters
25 Feb
BRIEF-BridgeBio Pharma To Offer $500 Million Convertible Senior Notes Due 2031

Feb 24 (Reuters) - BridgeBio Pharma Inc BBIO.O:

  • BRIDGEBIO INITIATES LONG TERM DEBT MANAGEMENT STRATEGY AND ANNOUNCES PROPOSED OFFERING OF CONVERTIBLE SENIOR NOTES TO REFINANCE SENIOR SECURED DEBT

  • BRIDGEBIO PHARMA INC - TO OFFER $500 MILLION CONVERTIBLE SENIOR NOTES DUE 2031

  • BRIDGEBIO PHARMA INC - OPTION TO PURCHASE ADDITIONAL $75 MILLION NOTES

  • BRIDGEBIO PHARMA INC - PROCEEDS TO REPAY AND TERMINATE FINANCING AGREEMENT

Source text: ID:nGNX8zfx71

Further company coverage: BBIO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10